Abstract:
Introduction: Gastrointestinal stromal tumors (GIST) represent
0.1-3% of all mesenchymal neoplasms of the gastrointestinal
tract and giant gastric (GG) GIST are rare. Purpose: Study of
clinical, histopathological and immunohistochemical features
and treatment results of GG GIST. Material and methods: 92
cases with GG GIST (c-kit(CD117)(+) treated between 2007-2019.
Conclusions: GG GIST are rare, but possess a higher risk of
progression. Complex treatment is the best curative option.
Keywords: giant GIST, complex treatment, high risk.
Results: A review of the database of 92 gastric GIST patients
with positivity to the specific marker c-KIT(CD117) was
performed. The study group consisted of 14 patients with GIST of
the stomach. M:F=1.8:1. Mean age-59.78±2.35 years.
Surgical options: excision of gastric tumor-2 (14,3%), gastric
wedge resection - 7 (50%), partial gastrectomy - 5 (35,7%). The
mean maximum size of tumors was 23.69±0.81 cm.
Immunohistochemical phenotype: CD117(+)-14(100%), CD34(+)
-12(85.7%), desmin(+)-3(21.4%), vimentin(+)-10(71.4%). Mean
number of mitoses–24.36±6.3. Tumors with high mitotic count
were registered more frequent than with low mitotic count –
11(78.6%) vs. 3(21.4%) (p<0.05). Metastases at first presentation
– 28.6%(n=4) cases. Complex treatment – surgery and imatinib
mesylate–in 14(100%) patients.
Conclusions: GG GIST are rare, but possess a higher risk of
progression. Complex treatment is the best curative option.
Description:
Department of gastric surgery, Department of Melanoma, Oncological Institute from Moldova, First Department of Surgery “N. Anestiadi” and Laboratory of Hepato-pancreato-biliary Surgery, SUMPh "N.Testemitanu", Institute of Emergency Medicine, Department of oncology, SUMPh "N.Testemitanu", Chișinău, Moldova, Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină și Farmacie „Nicolae Testemițanu” din Republica Moldova, Ziua internațională a științei pentru pace și dezvoltare